MKP-1 IN Regulation of Inflammatory Cytokine Production

Research Inst Nationwide Children'S Hosp, Columbus OH

Investigators

Linked publications & trials

Abstract

DESCRIPTION (provided by applicant): The long-term objective of this proposal is to understand the mechanisms responsible for the termination of proinflammatory cytokine biosynthesis in macrophages. Proinflammatory cytokines, TNF-alpha and IL-1 in particular, play an important role in the pathogenesis of a variety of human diseases, including rheumatoid arthritis, Crohn's disease, and septic shock. Biosyntheses of both TNF-alpha and IL-1 in LPS-stimulated macrophages are regulated by complex signal transduction pathways involving MAP kinases and NF-kappaB. Preliminary studies in our laboratory with RAW264.7 cells provide strong evidence to support the hypothesis that MKP-1 plays a critical role in the feedback control of p38 and JNK MAP kinases and is responsible for the termination of pro-inflammatory cytokine production in LPS-stimulated macrophages. Moreover, MKP-1 is potently induced by glucocorticoids. The First Specific Aim of the present proposal is to test the hypothesis that MKP-1 plays critical roles in restraining the LPS-induced biosynthesis of proinflammatory cytokines in two additional macrophage cell lines with characteristics of peritoneal and alveolar macrophages. The Second Specific Aim of this proposal is to test the hypothesis that LPS stimulates Mkp-1 transcription through a chromatin remodeling process involving histone H3 phosphoacetylation regulated by the ERK pathway. We will determine the role of histone H3 phosphorylation/acetylation in the transcriptional induction of Mkp-1 stimulated by LPS, using the RAW264.7 macrophage model. The Third Specific Aim is to test the hypothesis that MKP-1 also acts as a critical negative regulator in the restraint of macrophage responses to Gram-positive bacteria. The Fourth Specific Aim is to test the hypothesis that the responses to LPS stimulation of primary peritoneal macrophages from Mkp-1-/- mice differ from the responses of macrophages isolated from Mkp-1+/+ mice. The Mkp-1 knockout mice are available from Bristol-Myers Squibb Pharmaceutical Research Institute, through a materials transfer agreement. We will isolate peritoneal macrophages from the Mkp-1+/+ and Mkp-1-/- mice and use these macrophages to determine the role of MKP-1 in the responses to LPS, with respect to MAP kinase inactivation and control of inflammatory cytokine production. We will also examine whether the lack of Mkp-1 gene will compromise the suppressant effects of glucocorticoids on TNF-alpha production induced by LPS. These studies are designed to answer pivotal questions regarding the regulatory mechanisms responsible of terminating cytokine production in macrophages during bacterial infections, and to reveal novel targets for developing new anti-inflammatory/anti-rheumatic drugs.